Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference

Derek Archila
Senior Equity Analyst

All right, everyone. I think we’ll get started here with our next fireside discussion. My name is Derek Archila. I’m the senior biotech analyst here at Wells. Looking forward to our next discussion here with Soleno Therapeutics. From the company, we have Anish Bhatnagar, the CEO; as well as James MacKaness, the CFO. Gentlemen, thank you so much for joining us and looking forward to the discussion.

Anish Bhatnagar
Chairman, President, CEO & COO

Thanks for having us, Derek.

Derek Archila
Senior Equity Analyst

All right. Well, maybe, Anish, if you want to just start us off, a lot has been going on with Soleno, approval of your first drug, VYKAT and Prader-Willi Syndrome, ongoing launch. So maybe just kind of talk about what’s kind of going on before we dive into the Q&A here.

Anish Bhatnagar
Chairman, President, CEO & COO

Sure. So Soleno, as you know, is in the Prader-Willi space. We’re a rare disease company. We have a single asset, which has recently been approved. We got FDA approval in — at the end of March, and we launched shortly thereafter, a couple of weeks after that. We had our Q2 results that were announced a few weeks ago. And the launch has been going really well. We’ve had, in those 3 months or so, 646 start forms, 295 prescribers. So definitely exceeded our expectations. And in general, really excited to see this drug finally come to market in a disease where nothing has worked.